Cyclo Cash Flow To Debt Ratio from 2010 to 2024

CYTHW Stock  USD 0.13  0.01  7.14%   
Cyclo Therapeutics Cash Flow To Debt Ratio yearly trend continues to be fairly stable with very little volatility. Cash Flow To Debt Ratio will likely drop to -18.92 in 2024. During the period from 2010 to 2024, Cyclo Therapeutics Cash Flow To Debt Ratio regression line of quarterly data had mean square error of  2,961 and geometric mean of  7.61. View All Fundamentals
 
Cash Flow To Debt Ratio  
First Reported
2010-12-31
Previous Quarter
(18.02)
Current Value
(18.92)
Quarterly Volatility
55.41981219
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Cyclo Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cyclo Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 18.3 K, Interest Expense of 181.7 K or Total Revenue of 995.2 K, as well as many indicators such as Price To Sales Ratio of 25.33, Dividend Yield of 0.0 or PTB Ratio of 7.66. Cyclo financial statements analysis is a perfect complement when working with Cyclo Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Cyclo Therapeutics Correlation against competitors.
For more information on how to buy Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.

Latest Cyclo Therapeutics' Cash Flow To Debt Ratio Growth Pattern

Below is the plot of the Cash Flow To Debt Ratio of Cyclo Therapeutics over the last few years. It is Cyclo Therapeutics' Cash Flow To Debt Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cyclo Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Cash Flow To Debt Ratio10 Years Trend
Slightly volatile
   Cash Flow To Debt Ratio   
       Timeline  

Cyclo Cash Flow To Debt Ratio Regression Statistics

Arithmetic Mean(47.33)
Geometric Mean7.61
Coefficient Of Variation(117.08)
Mean Deviation49.43
Median(18.02)
Standard Deviation55.42
Sample Variance3,071
Range126
R-Value(0.32)
Mean Square Error2,961
R-Squared0.10
Significance0.24
Slope(4.01)
Total Sum of Squares42,999

Cyclo Cash Flow To Debt Ratio History

2024 -18.92
2023 -18.02
2022 -15.67
2021 -98.88
2020 -53.87
2016 -125.49
2015 -2.7

About Cyclo Therapeutics Financial Statements

Cyclo Therapeutics investors use historical fundamental indicators, such as Cyclo Therapeutics' Cash Flow To Debt Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Cyclo Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cash Flow To Debt Ratio(18.02)(18.92)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Cyclo Stock Analysis

When running Cyclo Therapeutics' price analysis, check to measure Cyclo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclo Therapeutics is operating at the current time. Most of Cyclo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cyclo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclo Therapeutics' price. Additionally, you may evaluate how the addition of Cyclo Therapeutics to your portfolios can decrease your overall portfolio volatility.